View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Zumtobel Ag: 1 director

A director at Zumtobel Ag bought 4,000 shares at 6.500EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Zumtobel confirmed at BUY, TP EUR 10 - Guidance upgrade warrants confi...

Zumtobel reported strong preliminary Q2 22/23 results and continued its series of convincing quarterly results. Ignited by the strong H1, the management raised the full-year guidance. We have raised our FY 22/23e EBIT to EUR 61 mn but deliberately did not stretch to the upper end of the guidance, which entails a further 20% upside (and suggests EPS of approx. EUR 1-1.10) We subscribe to concerns that the interest rate hike cycle will drag on European non-residential construction activity but we ...

Zumtobel prelim. Q2 22/23 - Strong prelim. Q2 results fuel FY guidance...

Revenue growth of 13% to EUR 314 mn spurred by pricing and FX effects Acceleration of Lighting sales growth as main driver Margin expansion to 10.1% in Q2 looks convincing, EBIT of ca EUR 51 mn already pocketed in H1 FY 22/23 top line growth outlook raised to 4-8% from 3-6% EBIT margin target up to 4-6% from 4-5% The strong results and the guidance upgrade are supportive for our positive stance on the investment case

Zumtobel Q1 22/23 - In-line Q1 results and guidance reiteration

Revenue growth of 8% marginally ahead of RBIe, earnings fully in line FY 22/23 top line growth of 3-6% and EBIT margin of 4-5% maintained, RBIe EBIT of EUR 56 mn at mid-point of guidance We have a mostly neutral stance on the results release

Raiffeisen Research Institutional Equity Daily 06.09.2022

 AT: Zumtobel - Q1 22/23 results fully in line with RBIe, FY guidance of sales up 3-6% and EBIT margin of 4-5% confirmed (neutral)  CZ: CTP - Plan to double German portfolio by 2026 (neutral)  Oil&Gas: OPEC+ meeting - The oil cartel to cut production by 100 kbbl/day in October  PL: Banks - WIRD Index likely to replace WIBOR as a reference rate for mortgages already in 2023 (neutral)  PL: LPP - CFO mentions positive sales trends in September (positive)  PL: PKN - Facing a further normaliza...

Zumtobel Q4 21/22 - Guidance beat, implied 22/23 target EBIT range in ...

Q4 results ahead of expectations despite one-off burden, still guidance exceeded Dividend increase to EUR 0.35 (5% yield) from EUR 0.20 FY 22/23 top line growth of 3-6% and EBIT margin of 4-5% imply EBIT of EUR 47-61 mn, in line with RBIe of EUR 56 mn We appreciate the solid outlook which given current circumstances might not be overly aggressive at this early stage

Raiffeisen Research Institutional Equity Daily 01.07.2022

 AT: Andritz - Andritz acquried Bonetti group (neutral)  AT: Andritz - Andritz to supply fiberline and lime kiln equipment to Sun Paper, China (neutral)  AT: UBM - UBM sells project and construction management subsidiary Alba (neutral)  AT: Wienerberger - Strong Q2 results trigger FY EBITDA guidance upgrade (positive)  AT: Zumtobel - Better than expected Q4 results despite higher warranty costs, FY 21/22 guidance beat, implied FY 22/23 EBIT range in line with RBIe (positive)  CZ: CEZ - CEZ...

Raiffeisen Research Institutional Equity Daily 10.06.2022

 AT: IMMOFINANZ - No FY 21 dividend, lack of support from CPI Property Group (negative)  AT: Zumtobel - Marcus Frantz appointed as Chief Digital Transformation Officer (neutral)  PL: Banks - Lower chamber of PL Parliament approves moratoria framework (neutral)  PL: Dino/Eurocash - Discounters and local supermarkets experience double digit growth (positive/neutral)  RO: One United Properties - The maximum subscription price for the first phase will be RON 1.42 per share (neutral)

Raiffeisen Research Institutional Equity Daily 31.05.2022

 MSCI May Index Review - Standard indices (STD) changes: DEL: Raiffeisen Bank Intl.; SmallCap indices (SC) changes: ADD: STRABAG SE, DEL: Zumtobel  Oil&Gas: Oil price - EU agreed to ban most of Russia oil imports  AT: STRABAG - Double digit output growth and backlog at new high in Q1, FY 22 guidance reiterated (positive)  CZ: Moneta Money Bank - PPF and Moneta terminate the acquisition of AirBank group / cancelation of the capital increase and mandatory tender offer by PPF  HU: Makro - Ra...

Raiffeisen Research Institutional Equity Daily 13.05.2022

 MSCI May Index Review - Standard indices (STD) changes: DEL: Raiffeisen Bank Intl.; SmallCap indices (SC) changes: ADD: STRABAG SE, DEL: Zumtobel  AT: AGRANA - Final FY 21/22 results match preliminary figures, FY 22/23e guidance confirmed (neutral)  AT: AT&S - AT&S proposed dividend of EUR 0.90/share for 2021/22e (neutral)  AT: Oesterreichische Post - Final Q1 22 numbers in line with prliminary figures, outlook reiterated (neutral)  AT: Palfinger - Takeover of remaining 35% stake in French...

Zumtobel confirmed at BUY, TP EUR 10 - Model update post Q3: Trimming ...

Zumtobel presented convincing Q3 results and the management displayed confidence to reach the upper end of the FY 21/22 top line and profitability ranges, potentially even exceed them We have raised our estimates for this year but foremost reflecting the highly inflationary cost environment and some sequentially more adverse FX movements we have now modelled a profit stagnation for FY 22/23e While we adopt a more conservative stance on next year we believe that the beyond peak inflationary press...

Zumtobel Q3 21/22 - Major beat in Q3 and more confident outlook

Blowout beat in Q3 aided by shift of R&D grants from Q2 into Q3 Clean margin still well above expectations Cash flow drain from much higher inventories FY 21/22 revenues and EBIT margin seen at the upper end of the respective ranges but could well be exceeded

Raiffeisen Research Institutional Equity Daily 08.03.2022

 AT: Andritz - Results above expectations and a positive outlook that contradicts our recent cautious stance (positive)  AT: Frequentis - Frequentis announces dividend of EUR 0.20 per share, as expected (neutral)  AT: IMMOFINANZ - CPI increases stake to 54.9%, calls for EGM for supervisory board elections (neutral)  AT: Vienna Insurance Group - Headline results in line with pre-released figures, dividend ahead of expectations (neutral)  AT: Zumtobel - Blowout beat in Q3 aided by shift of gr...

With a more favourable environment, ZUMTOBEL improves to Slightly Posi...

ZUMTOBEL (AT), a company active in the Electrical Components & Equipment industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date January 14, 2022, the closing price was EUR 8.26 and ...

Zumtobel confirmed at BUY, TP EUR 11 - Supply bottlenecks hold back st...

Bottlenecks for certain high-end components that have been flagged previously to have a stronger impact in Q2-3, prevent the realisation of higher revenues for now As regards the FY 21/22 outlook management acknowledged that top-line growth should be at the upper end of the 4-7% corridor, while the EBIT margin is expected to rather reach the lower end of the 4-5% range The group should increasingly benefit from price hikes. Management remarks suggest that order intake momentum remains very satis...

Zumtobel Q2 21/22 - Top line held back by bottlenecks in Q2

5% top line growth in Q2 below forecasts and implies sequentially weaker momentum FY 21/22 outlook of a 4-7% revenue increase and a 4-5% EBIT margin reiterated However, management envisages top line rather at upper end and profitability rather at lower end of the respective corridors As outlined on previous occasions, semiconductor shortage to remain a headwind with negative implications on product mix Unchanged favourable demand and order intake trends

Raiffeisen Research Institutional Equity Daily 07.12.2021

 AT: IMMOFINANZ, S IMMO - S IMMO to launch partial takeover offer for IMMOFINANZ (positive, negative)  AT: Zumtobel - Q2 revenue momentum held back by supply bottlenecks but good margin containment, FY 21/22 outlook confirmed (neutral)  RO: OMV Petrom - The 2030 strategy will enable high CF generation to ensure transition to a low carbon economy and attractive shareholder returns (positive)

Raiffeisen Research Institutional Equity Daily 13.10.2021

 EU: Utilities - EU Commission to present measures against increasing energy prices today (neutral)  AT: AT&S - Apple rumoured to cut iPhone 13 production target by 10 mn on supply chain shortage (negative)  AT: BAWAG Group - Pre earnings Q3 call with the management (neutral)  AT: Flughafen Wien - September passenger numbers at 53% of 2019 levels (positive)  AT: Frequentis - Frequentis and Airbus selected for phase III of the European Broadway interoperable broadband PPDR communication syst...

Zumtobel Company News - Ambitious growth outlook presented at the CMD

Zumtobel presented ambitious sales growth and margin targets, both much better than what has been achieved in the last decade Top line CAGR of 4-5% and EBIT margin of 6-8% targeted by FY 24/25 - RBIe stands at 3% and 6%, respectively Capital allocation: M&A angle, capex containment and dividend policy Overall, it became apparent that Zumtobel emerges into a growth-oriented phase

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch